94 related articles for article (PubMed ID: 30160591)
1. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Putkonen M; Partanen A; Pyörälä M; Savolainen ER; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
Leuk Lymphoma; 2019 Feb; 60(2):453-461. PubMed ID: 30160591
[TBL] [Abstract][Full Text] [Related]
2. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
[TBL] [Abstract][Full Text] [Related]
3. Blood graft composition after plerixafor injection in patients with NHL.
Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
[TBL] [Abstract][Full Text] [Related]
4. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.
Tolomelli G; Mancuso K; Tacchetti P; Patriarca F; Galli M; Pantani L; Zannetti B; Motta MR; Rizzi S; Dan E; Sinigaglia B; Giudice V; Olmo A; Arpinati M; Chirumbolo G; Fanin R; Lewis RE; Paris L; Bonifazi F; Cavo M; Curti A; Lemoli RM
Bone Marrow Transplant; 2020 May; 55(5):946-954. PubMed ID: 31768009
[TBL] [Abstract][Full Text] [Related]
5. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
Valtola J; Varmavuo V; Ropponen A; Nihtinen A; Partanen A; Vasala K; Lehtonen P; Penttilä K; Pyörälä M; Kuittinen T; Silvennoinen R; Nousiainen T; Pelkonen J; Mäntymaa P; Jantunen E
Transfusion; 2015 Oct; 55(10):2358-68. PubMed ID: 26018461
[TBL] [Abstract][Full Text] [Related]
6. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.
Shah H; Kim S; Singh P; Alavi A; Ratanatharathorn V; Ayash L; Uberti J; Deol A
Am J Hematol; 2020 Feb; 95(2):198-204. PubMed ID: 31691333
[TBL] [Abstract][Full Text] [Related]
8. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
[TBL] [Abstract][Full Text] [Related]
9. Impact of lenalidomide-based induction therapy on the mobilization of CD34
Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CD34
Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
[TBL] [Abstract][Full Text] [Related]
11. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
[TBL] [Abstract][Full Text] [Related]
12. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
Jantunen E; Fruehauf S
Bone Marrow Transplant; 2011 May; 46(5):627-35. PubMed ID: 21217789
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
Tricot G; Cottler-Fox MH; Calandra G
Bone Marrow Transplant; 2010 Jan; 45(1):63-8. PubMed ID: 19543330
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
[TBL] [Abstract][Full Text] [Related]
16. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma.
Song GY; Jung SH; Ahn SY; Jung SY; Yang DH; Ahn JS; Kim HJ; Lee JJ
BMC Cancer; 2019 Jan; 19(1):59. PubMed ID: 30642286
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
18. Impact of the number of cryopreserved CD34
Partanen A; Turunen A; Silvennoinen R; Valtola J; Pyörälä M; Siitonen T; Sikiö A; Putkonen M; Sankelo M; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
J Clin Apher; 2023 Feb; 38(1):33-44. PubMed ID: 36239392
[TBL] [Abstract][Full Text] [Related]
19. Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34
Salzmann-Manrique E; Bremm M; Huenecke S; Stech M; Orth A; Eyrich M; Schulz A; Esser R; Klingebiel T; Bader P; Herrmann E; Koehl U
Front Immunol; 2018; 9():1841. PubMed ID: 30154788
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]